Head-To-Head Contrast: Addex Therapeutics (OTCMKTS:ADDXF) & Acrivon Therapeutics (NASDAQ:ACRV)

Acrivon Therapeutics (NASDAQ:ACRV) and Addex Therapeutics (OTCMKTS:ADDXF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Earnings & Valuation

This table compares Acrivon Therapeutics and Addex Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$60.39 million	($2.70)	-2.58
Addex Therapeutics	N/A	N/A	N/A	N/A	N/A

Risk & Volatility

Acrivon Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Acrivon Therapeutics and Addex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	0	0	6	0	3.00
Addex Therapeutics	0	0	0	0	0.00

Acrivon Therapeutics presently has a consensus price target of $23.67, suggesting a potential upside of 240.04%. Given Acrivon Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Addex Therapeutics.

Profitability

This table compares Acrivon Therapeutics and Addex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-47.95%	-43.73%
Addex Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Acrivon Therapeutics beats Addex Therapeutics on 6 of the 8 factors compared between the two stocks.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

About Addex Therapeutics

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.